Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

Dear S.R.: Tirzepatide (Zepbound), like semaglutide, is a prescription medication originally used for diabetes but now ...

Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo ...

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...

The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial ...

This is a prescription medication originally used for diabetes but now approved for weight loss. Most people regained weight ...